DMAAR — Drugs Made In America Acquisition Corp.

—
Nasdaq · Financials · Diversified Financial Services · CIK 2028614 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,863,831 0 -136,934 1,726,897 146,903,435 20,280 9,136,624
Mar 2026 2,113,760 0 -143,301 1,970,459 242,035,303 14,887 7,392,169
Sep 2025 2,448,266 0 -263,703 2,184,563 237,632,428 — 7,356,611
Jun 2025 2,420,498 0 -131,919 2,288,579 235,205,692 822 7,201,441

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 8,756,656 -2,816,013 5,940,643 239,918,847 7,276,172 232,642,675 —
Dec 2024 — — — 550,824 795,669 -244,845 —

TTM Snapshot

Revenues TTM
$8,728,281
NetIncome TTM
$6,094,877
OpCashFlow TTM
—
Assets (Latest)
$146,903,435
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
HASI HA Sustainable Infrastructure Capital, Inc. $4.86B $38.01 —
DMII Drugs Made In America Acquisition II Corp. $652.61M $10.24 —
EVAC EQV Ventures Acquisition Corp. II $486.85M $10.37 —
BCSS Bain Capital GSS Investment Corp. $480.73M $10.25 —
CEPF Cantor Equity Partners IV, Inc. $473.69M $10.32 —

Recent Insider Activity

No insider activity indexed for this ticker.